PA
BCRX icon

Parallel Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parallel Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$900 Buy
90
+39
+76% +$353 ﹤0.01% 3704
2026
Q1 		$486 Sell
51
-42
-45% -$326 ﹤0.01% 3677
2025
Q4 		$725 Sell
93
-50
-35% -$361 ﹤0.01% 3355
2025
Q3 		$1.08K Buy
143
+50
+54% +$416 ﹤0.01% 3200
2025
Q2 		$833 Sell
93
-43
-32% -$400 ﹤0.01% 3230
2025
Q1 		$1.02K Buy
136
+43
+46% +$347 ﹤0.01% 3115
2024
Q4 		$699 Sell
93
-31
-25% -$235 ﹤0.01% 3170
2024
Q3 		$942 Buy
124
+31
+33% +$236 ﹤0.01% 3055
2024
Q2 		$575 Buy
+93
New +$513 ﹤0.01% 3074
2023
Q4 		– Sell
-40
Closed -$283 – 3337
2023
Q3 		$283 Buy
40
+13
+48% +$93 ﹤0.01% 3193
2023
Q2 		$190 Buy
+27
New +$217 ﹤0.01% 3243
2022
Q4 		– Sell
-10
Closed – – 3362
2022
Q3 		$0 Buy
+10
New +$129 ﹤0.01% 3144
2022
Q2 		– Sell
-9
Closed – – 3000
2022
Q1 		$0 Buy
+9
New +$144 ﹤0.01% 2972
2021
Q4 		– Sell
-18
Closed – – 3084
2021
Q3 		$0 Buy
+18
New +$284 ﹤0.01% 3075

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Parallel Advisors's BCRX Position: Q2 2026 in Review

Parallel Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 76% in Q2 2026, buying an estimated $353 and bringing the position to 90 shares worth $900. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Parallel Advisors first reported a position in BCRX in Q3 2021 and has held it in 14 quarters since. The position peaked at $1.08K in Q3 2025. 115 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Parallel Advisors held 90 shares of BioCryst Pharmaceuticals worth $900 as of Q2 2026.
  • Parallel Advisors bought 39 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $353.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3704 holding.
  • Parallel Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
  • Parallel Advisors's BioCryst Pharmaceuticals position peaked at $1.08K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.